BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 29170140)

  • 21. Long-term delivery of all-trans-retinoic acid using biodegradable PLLA/PEG-PLLA blended microspheres.
    Choi Y; Kim SY; Kim SH; Lee KS; Kim C; Byun Y
    Int J Pharm; 2001 Mar; 215(1-2):67-81. PubMed ID: 11250093
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting Pin1 by inhibitor API-1 regulates microRNA biogenesis and suppresses hepatocellular carcinoma development.
    Pu W; Li J; Zheng Y; Shen X; Fan X; Zhou JK; He J; Deng Y; Liu X; Wang C; Yang S; Chen Q; Liu L; Zhang G; Wei YQ; Peng Y
    Hepatology; 2018 Aug; 68(2):547-560. PubMed ID: 29381806
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preparation and evaluation of polymer based microcarriers for all-trans-retinoic acid.
    Daşkın D; Gündüz U
    Pharm Dev Technol; 2013; 18(5):1017-25. PubMed ID: 22428994
    [TBL] [Abstract][Full Text] [Related]  

  • 24. pH-sensitive niosomes for ATRA delivery: A promising approach to inhibit Pin1 in high-grade serous ovarian cancer.
    Giuli MV; Hanieh PN; Forte J; Fabiano MG; Mancusi A; Natiello B; Rinaldi F; Del Favero E; Ammendolia MG; Marianecci C; Checquolo S; Carafa M
    Int J Pharm; 2024 Jan; 649():123672. PubMed ID: 38052280
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pin1 inhibition reverses the acquired resistance of human hepatocellular carcinoma cells to Regorafenib via the Gli1/Snail/E-cadherin pathway.
    Wang J; Zhang N; Han Q; Lu W; Wang L; Yang D; Zheng M; Zhang Z; Liu H; Lee TH; Zhou XZ; Lu KP
    Cancer Lett; 2019 Mar; 444():82-93. PubMed ID: 30583078
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impairment of the Pin1/E2F1 axis in the anti-proliferative effect of bortezomib in hepatocellular carcinoma cells.
    Farra R; Dapas B; Baiz D; Tonon F; Chiaretti S; Del Sal G; Rustighi A; Elvassore N; Pozzato G; Grassi M; Grassi G
    Biochimie; 2015 May; 112():85-95. PubMed ID: 25742740
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pin1-Targeted Therapy for Systemic Lupus Erythematosus.
    Wei S; Yoshida N; Finn G; Kozono S; Nechama M; Kyttaris VC; Zhen Zhou X; Tsokos GC; Ping Lu K
    Arthritis Rheumatol; 2016 Oct; 68(10):2503-13. PubMed ID: 27159270
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tumor-targeted paclitaxel-loaded folate conjugated poly(ethylene glycol)-poly(L-lactide) microparticles produced by supercritical fluid technology.
    Huang X; Zhang Y; Yin G; Pu X; Liao X; Huang Z; Chen X; Yao Y
    J Mater Sci Mater Med; 2015 Feb; 26(2):95. PubMed ID: 25649516
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Resistance of hepatocellular carcinoma to sorafenib can be overcome with co-delivery of PI3K/mTOR inhibitor BEZ235 and sorafenib in nanoparticles.
    Wu B; Li A; Zhang Y; Liu X; Zhou S; Gan H; Cai S; Liang Y; Tang X
    Expert Opin Drug Deliv; 2020 Apr; 17(4):573-587. PubMed ID: 32056461
    [No Abstract]   [Full Text] [Related]  

  • 30. GSK-126 Enhances All-Trans-Retinoic Acid (ATRA) Response in Hepatocellular Carcinoma (HCC) by Upregulating
    Liu Z; Zheng Y
    Discov Med; 2024 May; 36(184):1041-1053. PubMed ID: 38798263
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting PIN1 exerts potent antitumor activity in pancreatic ductal carcinoma via inhibiting tumor metastasis.
    Chen L; Xu X; Wen X; Xu S; Wang L; Lu W; Jiang M; Huang J; Yang D; Wang J; Zheng M; Zhou XZ; Lu KP; Liu H
    Cancer Sci; 2019 Aug; 110(8):2442-2455. PubMed ID: 31148345
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chemopreventive efficacy of all-trans-retinoic acid in biodegradable microspheres against epithelial cancers: results in a 4-nitroquinoline 1-oxide-induced oral carcinogenesis model.
    Choi Y; Kim SY; Park K; Yang J; Cho KJ; Kwon HJ; Byun Y
    Int J Pharm; 2006 Aug; 320(1-2):45-52. PubMed ID: 16730144
    [TBL] [Abstract][Full Text] [Related]  

  • 33. miR-874-3p is down-regulated in hepatocellular carcinoma and negatively regulates PIN1 expression.
    Leong KW; Cheng CW; Wong CM; Ng IO; Kwong YL; Tse E
    Oncotarget; 2017 Feb; 8(7):11343-11355. PubMed ID: 28076852
    [TBL] [Abstract][Full Text] [Related]  

  • 34. All-
    Kim G; Bhattarai PY; Oh CH; Choi HS
    Anticancer Res; 2019 Dec; 39(12):6537-6546. PubMed ID: 31810919
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A novel hybrid delivery system: polymer-oil nanostructured carrier for controlled delivery of highly lipophilic drug all-trans-retinoic acid (ATRA).
    Narvekar M; Xue HY; Wong HL
    Int J Pharm; 2012 Oct; 436(1-2):721-31. PubMed ID: 22850294
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tailoring the properties of mPEG-PLLA nanoparticles for better encapsulation and tuned release of the hydrophilic anticancer drug.
    Surwase SS; Munot NM; Idage BB; Idage SB
    Drug Deliv Transl Res; 2017 Jun; 7(3):416-427. PubMed ID: 28324320
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Activation of AMP-activated protein kinase by retinoic acid sensitizes hepatocellular carcinoma cells to apoptosis induced by sorafenib.
    Ishijima N; Kanki K; Shimizu H; Shiota G
    Cancer Sci; 2015 May; 106(5):567-75. PubMed ID: 25683251
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bufalin-loaded mPEG-PLGA-PLL-cRGD nanoparticles: preparation, cellular uptake, tissue distribution, and anticancer activity.
    Yin P; Wang Y; Qiu Y; Hou L; Liu X; Qin J; Duan Y; Liu P; Qiu M; Li Q
    Int J Nanomedicine; 2012; 7():3961-9. PubMed ID: 22888239
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preparation, characterization and in vitro cytotoxicity of indomethacin-loaded PLLA/PLGA microparticles using supercritical CO2 technique.
    Kang Y; Wu J; Yin G; Huang Z; Yao Y; Liao X; Chen A; Pu X; Liao L
    Eur J Pharm Biopharm; 2008 Sep; 70(1):85-97. PubMed ID: 18495445
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Micellar complexes of all-trans retinoic acid with polyvinylalcohol-nicotinoyl esters as new parenteral formulations in neuroblastoma.
    Zuccari G; Bergamante V; Carosio R; Gotti R; Montaldo PG; Orienti I
    Drug Deliv; 2009 May; 16(4):189-95. PubMed ID: 19241235
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.